Comparative Pharmacology
Head-to-head clinical analysis: ARYMO ER versus VICOPRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARYMO ER versus VICOPRIN.
ARYMO ER vs VICOPRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARYMO ER (morphine sulfate) is a full opioid agonist that binds to mu-opioid receptors in the central nervous system (CNS), inhibiting ascending pain pathways and altering pain perception. It also activates descending inhibitory pathways.
VICOPRIN (hydrocodone/acetaminophen) combines a mu-opioid receptor agonist (hydrocodone) that inhibits ascending pain pathways and alters pain perception, with an analgesic and antipyretic (acetaminophen) that inhibits cyclooxygenase (COX) and central prostaglandin synthesis.
15 mg to 30 mg orally every 12 hours; titrate to effect; maximum 60 mg per dose.
1 to 2 tablets (each containing 7.5 mg hydrocodone bitartrate and 200 mg ibuprofen) orally every 4 to 6 hours as needed for pain; maximum 5 tablets per day.
None Documented
None Documented
Terminal elimination half-life is approximately 11–13 hours in healthy adults. This extended half-life compared to immediate-release morphine (2–4 hours) allows for once-daily dosing. In elderly or hepatic/renal impairment, half-life may be prolonged up to 22 hours.
Hydrocodone: 3.8-6.0 hours in adults; acetaminophen: 2.0-4.0 hours. Clinically, Vicoprofen (hydrocodone/ibuprofen) has an effective half-life of ~4-6 hours for hydrocodone; ibuprofen half-life is 2-4 hours.
Primarily renal (90%), with approximately 10% excreted unchanged in urine; the remainder as glucuronide conjugates (morphine-3-glucuronide, morphine-6-glucuronide) and minor metabolites. Biliary/fecal excretion accounts for <10%.
Renal excretion of metabolites (hydrocodone: ~60% as conjugates; acetaminophen: ~85-90% as glucuronide and sulfate conjugates). Biliary/fecal elimination accounts for <5%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic